Janssen registers Ramantamig and Daratumumab versus DVRd trial in newly diagnosed multiple myeloma
The study, led by Janssen Research & Development, LLC, plans to enroll 1000 participants and is scheduled to start on December 14, 2026. It compares Ramantamig plus Daratumumab with the standard DVRd regimen followed by high-dose therapy, autologous stem cell transplant, and maintenance therapy.
Primary source
ClinicalTrials.gov registry record, October 29, 2026
A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
Machine-summarized from the source above; not independently reported. How we use automation